FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
MWN-AI** Summary
Innocan Pharma Corporation, a leader in the pharmaceutical and biotechnology sectors, has announced that the FDA's Center for Veterinary Medicine (CVM) has granted it a fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year in 2026. This waiver is part of the FDA's "significant barrier to innovation" provision, which permits sponsors developing groundbreaking products to request annual fee waivers. Each year, Innocan submits updates on its development progress, and the recent renewal highlights the company's ongoing commitment to innovation in animal health.
The fee waiver pertains to Innocan's LPT-CBD, a drug candidate aimed at providing relief for chronic pain in dogs through a subcutaneous injection. Positive results from a recent blinded, crossover study demonstrate LPT-CBD's potential, showing a statistically significant reduction in pain among osteoarthritic dogs when compared to a placebo. These findings provide robust evidence for its effectiveness and suitability as a treatment option in veterinary medicine.
Dr. Antonio Benitz, an advisor for Innocan's animal health initiatives, noted that the veterinary market is increasingly receptive to new drug technologies that can improve upon current pain management solutions. With rising pet ownership in the U.S.—with around 94 million households owning pets—Innocan's LPT-CBD could address the urgent need for safe and effective chronic pain management alternatives.
As the company continues to advance its P-CBD technology amidst a growing demand for innovative veterinary solutions, the CVM's recognition amplifies Innocan's ongoing efforts to enhance the quality of life for pets suffering from chronic pain.
MWN-AI** Analysis
Innocan Pharma Corporation's recent announcement regarding the FDA's Center for Veterinary Medicine granting a fee waiver for its LPT-CBD product for the third consecutive year is a significant development, especially for investors looking to enter the veterinary pharmaceutical market. This waiver highlights Innocan's commitment to innovation within a sector that is increasingly competitive and focused on animal health solutions.
The LPT-CBD, which aims to manage chronic pain in dogs, has shown promising results in clinical trials, demonstrating statistically significant pain reduction. This positions Innocan strategically within the growing pet industry, where an estimated 94 million American households own pets. This market is not only sizeable but is also expected to expand, driven by rising pet ownership and an increasing demand for advanced therapeutic options.
Investors should note that the fee waiver reflects regulatory recognition of Innocan's innovation-driven focus, which is essential for maintaining a competitive edge in the veterinary pharmaceuticals sector. The emphasis on safety and efficacy in pain management solutions is vital, given the limitations of traditional therapies, including opioids.
However, investors must remain vigilant regarding potential risks. The pharmaceutical landscape is fraught with uncertainties such as regulatory hurdles, competition, and operational execution challenges. The company's forward-looking statements indicate ambitious plans for human trials and further market expansion, but these endeavors depend on successfully navigating regulatory pathways and ensuring production capabilities.
In conclusion, while Innocan Pharma's recent fee waiver is a positive indicator of its commercial potential in the veterinary market, prospective investors should assess both the considerable opportunities and inherent risks associated with this sector. Keeping informed about regulatory updates and clinical trial progress will be critical for evaluating Innocan’s future performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year.
The FDA's Center for Veterinary Medicine (CVM) assesses annual fees for animal drug applications. Sponsors developing innovative products may request a fee waiver each year under the "significant barrier to innovation" provision. Accordingly, every year Innocan submits an annual renewal request that includes a brief update on development progress and forward plans. Following review of the Company's latest submission, CVM has again granted Innocan a fee waiver for the year 2026. This represents the Company's third consecutive annual waiver, underscoring CVM's continued recognition of Innocan's innovation-driven animal health program.
The waiver relates to the Company's Liposomal Technology–CBD (LPT-CBD) drug product candidate, being developed as a subcutaneous injection for the management of chronic pain in dogs. In a blinded, crossover study conducted on osteoarthritic dogs, LPT-CBD demonstrated a statistically significant reduction in pain and meaningful improvements in overall well-being compared with placebo (empty liposomes) (1). Together with additional studies previously conducted in osteoarthritic dogs, these results provide robust evidence supporting LPT-CBD's analgesic potential and its suitability as a treatment option for chronic pain in dogs.
"The veterinary market is open to new drug technologies that can address the limitations of current pain medications and offer a new alternative therapy", Said Dr' Antonio Benitz, Innocan's animal health advisor. The fee waiver granted by CVM for the third time, recognizing LPT-CBD's innovation, reinforces Innocan's progress toward delivering a new solution for chronic pain in dogs.
Dr. Eyal Kalo, Vice President of Research and Development at Innocan added, "U.S. pet ownership continues to grow, with an estimated 94 million households owning at least one pet." (2) "Our technology is designed to meet rising demand for safe, effective chronic pain solutions, combining demonstrated therapeutic potential with the convenience of a single, once-monthly administration".
Reference:
(1) Yael Shilo-Benjamini et al, Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial, Front. Vet. Sci., 19 January 2026
About Innocan:
Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan carries on business through its 60% owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted online sales.
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Caution Regarding Forward-Looking Information
Certain information set forth in this news release, including, without limitation, the Company's plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.
Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan's public reports and filings which are available under Innocan's profile at www.sedarplus.ca.
Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.
Logo - https://mma.prnewswire.com/media/2570689/Innocan_Pharma_Logo.jpg
SOURCE Innocan Pharma Corporation
FAQ**
How does the FDA Center for Veterinary Medicine's decision to grant Innocan a fee waiver for 2026, marking the third consecutive year, impact the company's innovation strategy for its LPT-CBD product in the context of the growing pet health market, particularly considering the INNpD listing?
Given that Innocan has successfully received a fee waiver for three years, what specific advancements in the LPT-CBD product led to CVM's recognition, and how do these advancements align with the increasing demand for pet pain management solutions, especially with the INNpD focus?
In what ways does Innocan plan to leverage the ongoing fee waiver from the FDA in 2026 to expedite the development and commercialization of LPT-CBD, and how might this strategic move influence its market positioning amid increased competition, considering the INNpD designation?
How do the results of the blinded, crossover study on osteoarthritic dogs substantiate Innocan's approach to chronic pain management in pets, and what implications does this have for investor confidence, particularly relating to the company's performance under the INNpD ticker?
**MWN-AI FAQ is based on asking OpenAI questions about Innocan Pharma Corporation - Common Shares (CNQC: INNO:CC).
NASDAQ: INNO:CC
INNO:CC Trading
-3.39% G/L:
$0.57 Last:
40,595 Volume:
$0.55 Open:
INNO:CC Latest News
Thu, Feb 12, 2026 as of 10.00 am ET
Mon, Jan 26, 2026 as of 4:00 pm ET
